Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
214 results about "Antibiotics beta lactam" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Β-lactam antibiotics (beta-lactam antibiotics) are a class of broad-spectrum antibiotics, consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures. This includes penicillin derivatives (penams), cephalosporins (cephems), monobactams, and carbapenems.
Use of beta-lactamase
InactiveUS20090311234A1Eliminate side effectsAntibacterial agentsHydrolasesSide effectAntibiotic therapy
Class A beta-lactamase may be used for reducing side-effects in the intestine associated with antibiotic therapy with a combination of beta-lactam antibiotic and beta-lactamase inhibitor.
Owner:IPSAT THERAPIES
Beta-lactam antibiotic-containing tablet and production thereof
InactiveUS6423341B1Antibacterial agentsOrganic active ingredientsLow-substituted hydroxypropylcelluloseEngineering
This invention provides beta-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into water in a glass as well as a method of producing the same. The tablets of this invention comprise, on the per-tablet basis, 60-85% by weight of a beta-lactam antibiotic, 1-10% by weight of low-substituted hydroxypropylcellulose and / or crosslinked polyvinylpyrrolidone as a disintegrator, and 0.5-2% by weight of a binder. Granules to be compressed for tableting are prepared using water or an aqueous solution of ethanol or the like.
Owner:ASTELLAS PHARMA INC
Components and preparation method of beta-lactam injection
ActiveCN101721366AReduce the number of dosesReduce stressAntibacterial agentsSolution deliverySterile environmentVegetable oil
The invention discloses the components and preparation method of beta-lactam injection. The beta-lactam injection comprises 5 to 20 percent of beta-lactam antibiotics, 0.05 to 5 percent of suspending agent, 0.005 to 0.3 percent of antioxygen, 0.1 to 0.2 percent of nonionic surfactant and the balance of vegetable oil or grease for injection. The injection can be used for preventing and curing animal bacterial infectious diseases and can be injected hypodermically or in muscle and be applied through breast for a few times. The preparation method provided by the invention comprises: firstly, making the antibiotics and the antioxygen into micro powder and making the suspending agent into fine powder; secondly, adding the vegetable oil or grease for injection, which is sterilized at high temperature, into the fine powder of the suspending agent, heating the mixture, uniformly mixing the mixture and keeping the mixture in a sterile environment to cool the mixture to room temperature for later use; and finally, transferring the prepared oil or grease added with the suspending agent to a colloid mill, adding medicament micro powder, the antioxygen and the non-ionic surfactant with stirring, and performing uniform mixing and sterilization to obtain the beta-lactam injection.
Owner:LUOYANG HUIZHONG ANIMAL MEDICINE
Modified beta-lactamase and method for its preparation
The invention relates to targeted post translational modifi-cation of metallo-beta-lactamase by truncation and inser-tion of a dipeptide at the amino terminal end to reduce amino terminal heterogeneity in a recombinant DNA pro-duction system. A protein K-T-E-ΔBL is expressed, and modified by host proteases to E-ΔBL. Appropriate nucleotide molecules, vectors and hosts are also de-scribed. E-ΔBL is useful in a pharmaceutical composition for treating antibiotic induced adverse effects in the intes-tine of patients treated with beta-lactam antibiotics.
Owner:SYNTHETIC BIOLOGICS INC
Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers
InactiveUS20090156517A1Reduce formationMeet the requirementsAntibacterial agentsBiocideParticulatesAntibiotic Y
A pharmaceutical composition comprising: at least one aminoglycoside antibiotic and (a) at least one ion chelating agent used for inhibiting particulate formation, or (b) at least one buffer, or (c) at least one ion chelating agents and at least one buffer simultaneously. The composition for use in controlling microbial infection can be formulated into a solution, or combined with at least one beta-lactam antibiotic, or combined with at least one of beta-lactam antibiotic and at least one beta-lactamase inhibitor into a solution in a container.
Owner:ZHANG HESHENG
Modified beta-lactamase and method for its preparation
The invention relates to targeted post translational modification of metallo-beta-lactamase by truncation and insertion of a dipeptide at the amino terminal end to reduce amino terminal heterogeneity in a recombinant DNA production system. A protein K-T-E-ΔBL is expressed, and modified by host proteases to E-ΔBL. Appropriate nucleotide molecules, vectors and hosts are also described. E-ΔBL is useful in a pharmaceutical composition for treating antibiotic induced adverse effects in the intestine of patients treated with beta-lactam antibiotics.
Owner:SYNTHETIC BIOLOGICS INC
Pharmaceutical compositions
A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I):In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of beta lactam antibiotics against many beta-lactamase producing bacteria.
Owner:SMITHKLINE BECKMAN CORP
Modified beta-lactamases and methods and uses related thereto
The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects.Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.
Owner:SYNTHETIC BIOLOGICS INC
Antibiotic polymers
InactiveUS7396527B2Reduce frequencyReducing and eliminating riskPharmaceutical non-active ingredientsSynthetic polymeric active ingredientsPolyesterPolyamide
Polymers (i.e. polyesters, polyamides, polythioesters, polyanhydrides, or a mixture thereof) which degrade hydrolytically to provide a combination of a beta-lactam antibiotic (e.g., amoxicillin) and a beta-lactamase inhibitor (e.g., clavulanic acid) (or a pharmaceutically acceptable salt thereof) are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor (or a pharmaceutically acceptable salt thereof) to a host are also provided.
Owner:RUTGERS THE STATE UNIV
Process for The Preparation of Beta-Lactam Antibiotic
InactiveUS20090264643A1Simple and viable processSimple processAntibacterial agentsOrganic chemistryMeropenemAntibiotics beta lactam
Owner:ORCHID CHEM & PHARM LTD
Modified beta-lactamases and methods and uses related thereto
The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.
Owner:SYNTHETIC BIOLOGICS INC
Stable pharmaceutical composition comprising beta-lactam antibiotic and ion-chelating agent
InactiveUS20090155387A1Reduce formationAvoid drug resistanceAntibacterial agentsBiocideMedicineAntibiotic Y
A pharmaceutical composition comprising: at least one β-lactam antibiotic and at least one ion-chelating agent; wherein when said pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic.
Owner:ZHANG HESHENG
Novel broad-spectrum beta-lactamase inhibitor
ActiveCN105801610AAvoid failureEffective activityAntibacterial agentsBoron compound active ingredientsBeta lactam antibioticEconomic benefits
The invention discloses a novel broad-spectrum beta-lactamase inhibitor. The structure of the compound is shown in the formula I, by means of research on activity of six beta-lactamases in four types with the compound, it is found that the compound can inhibit activity of multiple beta-lactamases, when the compound is combined with beta-lactam antibiotics, the combination has powerful growth inhibiting activity on bacteria generating beta-lactamase, it can be expected that a drug which can recover antibacterial activity of the beta-lactam antibiotics to treat and prevent infection caused by bacteria of animals including human can be developed, and the novel broad-spectrum beta-lactamase inhibitor has great social and economic benefits.
Owner:WUHAN VISION PHARMA TECH CO LTD
Stable pharmaceutical composition comprising beta-lactam antibiotic and buffer
InactiveUS20090156518A1Prevent first-time-treatment failureEffective treatment regimenAntibacterial agentsBiocideMedicineAntibiotic Y
A pharmaceutical composition, comprising: at least one β-lactam antibiotic and at least one buffer component; wherein when the pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic mixed with the β-lactam antibiotic and the buffer component.
Owner:ZHANG HESHENG
Methods and Kits for Direct Detection and Susceptibility Profiling of Beta-Lactam Resistant Bacteria
InactiveUS20110245105A1Microbiological testing/measurementLibrary screeningBacteroidesBeta lactam resistant bacteria
The present invention relates to a convenient, flexible and cost-efficient technology for detection and resistance-profiling of bacteria, enabling effective, evidence-based treatment of infections. The invention provides methods and modular kits for the rapid and direct detection of beta-lactam resistant bacteria in a test sample, and optionally for susceptibility profiling of the bacteria, by directly determining hydrolysis product / s of beta-lactam antibiotic substrates in the tested sample. The invention also provides methods and modular kits for the rapid and direct detection of the presence of multidrug resistant bacteria in a test sample.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Kit for detecting beta-lactam antibiotic ligand in milk by receptor method and detection method thereof
ActiveCN101813698AShort detection timeHigh detection throughputDepsipeptidesTesting dairy productsPenicillin bindingDiluent
The invention discloses a kit for detecting beta-lactam antibiotic ligand in milk by a receptor method and a detection method thereof. The kit comprises the following components: (1) an enzyme-labeled plate which is coated by penicillin-binding protein PBP2xa or PBP2xb recombinant protein; (2) an enzyme-labeled marker; (3) standard solution of ampicillin sodium; (4) 20 times concentrated cleaning buffer solution; (5) enzyme-labeled diluent; (6) 20 times concentrated sample extract; (7) developing solution; and (8) reaction stop solution. The kit of the invention can simultaneously screen eight beta-lactam antibiotic residues in the milk; the detection limit is lower than the minimum residue limit of China and main developed countries in the world; the detection time is within 50 minutes; and the kit has the characteristics of simple, rapid and accurate operation, low cost and the like and is suitable for large-scale popularization and application.
Owner:上海溯源生物技术有限公司
Beta-lactamase inhibitors
InactiveUS20100261700A1Improve antibiotic activityGrowth inhibitionAntibacterial agentsOrganic active ingredientsBeta lactam antibioticInhibitory effect
Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
Owner:SOPHARMIA
Pharmaceutical composition for controlled release of a beta-lactam antibiotic
ActiveUS20050031685A1Maintenance characteristicAvoid disadvantagesBiocideDrug compositionsHydrophilic polymersWater dispersible
An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and one xanthan gum and with or without hydroxypropyl methylcellulose, said composition optionally containing probenecid. The composition may also contain one or more of a water soluble and / or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and / or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition.
Owner:LUPIN LTD
Beta-lactam twin antibiotic compound, preparation method thereof and use thereof
InactiveCN101723961AStrong antibacterial activityAvoid drug resistanceAntibacterial agentsOrganic chemistryChemical structureAntibacterial activity
The invention relates to the technical field of medicines, in particular to a twin antibiotic compound formed by bonding each two parent nucleuses with the same structure of a beta-lactam antibiotic compound or of a derivative of the beta-lactam antibiotic compound with a dicarboxylic acid by two amido bonds, preparation method thereof and use thereof. The chemical structural general formula of the twin antibiotic compound is represented by a formula III. In the formula, R3 is a parent nucleus structure of a molecule of a penicillin compound or a derivative of the penicillin compound or a molecule of a cephalosporin compound or a derivative of the cephalosporin compound; and R may be alkyl and aryl or heteroaryl or substituted alkyl and substituted aryl or heteroaryl. In-vitro antibacterial experiments show that the beta-lactam twin antibiotic compound of the invention has remarkable antibacterial activity and is a novel antibacterial compound. The beta-lactam twin antibiotic compound of the invention can be used in the preparation of bacteriostats or bacteriacides as well as anti-infection medicaments. According to the general knowledge of pharmacy, the compound of the invention can be made into pharmaceutically acceptable salts or hydrates.
Owner:刘超美
Method, special kit and test paper strip for detecting beta-lactam antibiotics based on penicillin-binding protein
ActiveCN102253216AHigh sensitivityImprove accuracyBiological testingAmpicillinBeta lactam antibiotic
The invention discloses a method, a special kit and test paper strips for detecting beta-lactam antibiotics based on penicillin-binding protein. The receptor kit used for detecting beta-lactam antibiotics comprises: protein represented by SEQ ID NO: 1, enzyme labeled ampicillin and a standard substance solution, wherein the standard substance is penicillin G. The kit and colloidal gold test paper strips provided by the invention have advantages of high sensitivity, high accuracy, high precision, low cost, simple operation, short detection period, simple storage, and long shelf-life. The kit and colloidal gold test paper strips are suitable for various work units. With the kit and colloidal gold test paper strips, simultaneous and rapid detections of large batches of samples can be realized, and on-site high flux rapid detections can be realized. Therefore, the kit, the colloidal gold test paper strips and the method provided by the invention play an important role in the detections of beta-lactam antibiotics.
Owner:北京维德维康生物技术有限公司 +1
Kit test method of beta-lactam antibiotics residue in milk
ActiveCN101633948ALow costQuick checkMicrobiological testing/measurementMicroorganism based processesSporeBeta lactam antibiotic
The invention discloses a kit test method of beta-lactam antibiotics residue in milk, comprising the following steps: performing once activation to bacillus stearothermophilus, then culturing the activated bacillus stearothermophilus in a production culture medium at 50-65 DEG C for 24-36h while stirring in a rotation speed of 100-150rpm, centrifugalizing to collect bacteria mire, adding agarose bromcresol purple solution, mixing evenly to ensure the number of spore in each kit reach 1.00*10<7>-2.50*10<8>cfu, subpackaging the spore in porous reaction vessels at 60-70 DEG C, covering aluminum-plastic film, placing upside down, sealing, placing the vessels in aluminum-plastic packages and storing in dark place while keeping from wet. The kit has the advantage of easy operation, high sensibility, good repeatability, low cost and high throughput, can be stored at 4-8 DEG C for 12-18 months and can be used to test beta-lactam antibiotics residue in milk.
Owner:GUANGDONG YANTANG DAIRY
Antibiotic polymers
InactiveUS20050100526A1Reduce frequencyReducing and eliminating riskPharmaceutical non-active ingredientsSynthetic polymeric active ingredientsPolyesterPolyamide
Polymers (i.e. polyesters, polyamides, polythioesters, polyanhydrides, or a mixture thereof) which degrade hydrolytically to provide a combination of a beta-lactam antibiotic (e.g., amoxicillin) and a beta-lactamase inhibitor (e.g., clavulanic acid) (or a pharmaceutically acceptable salt thereof) are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor (or a pharmaceutically acceptable salt thereof) to a host are also provided.
Owner:RUTGERS THE STATE UNIV
Method for preparing detection kit based on penicillin-binding protein PBP6 beta-lactam antibiotic receptor assay and detection method thereof
ActiveCN104215775AHigh sensitivityHigh detection sensitivityBiological testingAntibiotic YMacrolide resistance
The invention aims to provide a method for preparing a rapid detection kit based on penicillin-binding protein PBP6 beta-lactam antibiotic receptor assay as well as a used detection method, aiming at solving the problem of sieve leakage in the process of detecting beta-lactam medicines in a traditional ELISA method. The invention discloses a method for preparing a detection kit based on penicillin-binding protein PBP6 beta-lactam antibiotic receptor assay as well as an indirect competitive receptor assay method for detecting the content of beta-lactam drugs in milk by adopting the detection kit based on penicillin-binding protein PBP6 beta-lactam antibiotic receptor assay. The methods have the beneficial effects that by utilizing the characteristic that the penicillin-binding protein 6 can be specifically bound to the beta-lactam drugs, the drugs can be specifically identified in a buffer liquid system or a sample matrix extracting solution and are not influenced by other antibiotics such as macrolides, quinolones and tetracyclines.
Owner:北京纳百生物科技有限公司
Method of rapidly degrading beta-lactam antibiotic in water
ActiveCN107298478AGood removal effectReduce energy consumptionWater contaminantsWater/sewage treatment by oxidationPersulfateBiological activation
The invention relates to a method of rapidly degrading a beta-lactam antibiotic in water. The method concretely comprises the following steps: adding a certain quantity of peroxymonosulfate (PMS) as an oxidant in waste water which contains a beta-lactam antibiotic (such as cephalexin, i.e. CFX) at normal temperature and normal pressure, uniformly stirring, carrying out reaction for a period of time under a neutral condition while keeping a pH value of a system, and removing a pollutant with oxidative degradation. According to the method provided by the invention, the peroxymonosulfate as the oxidant has very high selectivity to the beta-lactam antibiotic, directly oxidizes and removes the pollutant without an additional persulfate activation step, is rapid in degradation with very little influence caused by other organic matters in a water body, and is more beneficial to removing the beta-lactam antibiotic in a polluted water body.
Owner:SUZHOU UNIV OF SCI & TECH
Miniaturized Staphylococcus aureus polypeptide of against drug resistance and its uses and preparation method
ActiveCN1766110AToxic reductionStrong bactericidal effectAntibacterial agentsPeptide/protein ingredientsBacteroidesEscherichia coli
The invention discloses a midget anti drug-tolerance staphylococcus aureus polypeptide comprised of passage structure domain to form ion channel colicine and staphylococcus aureu pheromone, as well as opposite coded nucleotide sequence and recombination plasmid contained said sequence. Wherein, the plupeptide can not induce bacteria to generate trsditional drug-tolerance by the mechnism that it forms directly ion channel on cell film of target cell to kill bacteria. This invention has more single antimicrobial spectrum without effect to Gram-negative bacteria of escherichia coli, shows at least 500 times effect to pheneazonecillin, and can be used as synergist to beta-lactam antibiotics.
Owner:畿晋庆堂国际生物技术有限公司
Method and kit for detecting, or determining the quantity of, beta-lactam penicillins
ActiveUS20030143653A1Biological material analysisPeptide preparation methodsBeta lactam antibioticLabelling
The invention provides a hapten comprising a 6-[D-alpha-aminoacetamido]penicillin derivative crosslinked at the alpha-amino group with a substituted or unsubstituted phenyldicarbaldehyde. In addition, the invention provides an immunogen comprising the aforementioned hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the aforementioned hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with at least one structural epitope of an intact beta-lactam ring. The invention further provides a method and a kit for detecting, or determining the quantity of, beta-lactam antibiotics, as well as, use of the aforementioned conjugate with the aforementioned antibodies for detecting, or determining the quantity of, beta-lactam antibiotics. The present invention has broad specificity across the main first generation beta-lactams and can be used to test milk and meat and the like for the presence of residual beta-lactam antibiotics.
Owner:NORTHERN BANK LTD
Dihydroarteannuin derivatives and application thereof
InactiveCN102675337AHigh antibacterial efficacyReverse drug resistanceAntibacterial agentsOrganic chemistryEscherichia coliBeta lactam antibiotic
The invention relates to synergistic dihydroarteannuin oxyethylimidazole derivatives and application thereof. The dihydroarteannuin oxyethylimidazole derivatives have the structure disclosed as one of Formulae I-III, and can be used for preparing an antimicrobial synergist for antibiotics. The dihydroarteannuin derivatives can inhibit growth of multidrug-resistant Escherichia coli when being used independently or combined with beta-lactam antibiotics, reverse the drug resistance of the antibacterial drug to bacteria, and enhance the antimicrobial efficacy of antibiotics.
Owner:ARMY MEDICAL UNIV
Application of macrolide compound or salt thereof and pharmaceutical composition containing macrolide compound or salt
ActiveCN104337826ADelay drug resistanceGood synergy in vitroAntibacterial agentsSugar derivativesChemical compoundBeta lactam antibiotic
Owner:SHANGHAI INST OF PHARMA IND +1
Broad spectrum beta-lactamase inhibitors
InactiveUS20090131394A1Improve antibiotic activityGrowth inhibitionAntibacterial agentsBiocideBeta lactam antibioticMedicinal chemistry
Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
Owner:GLADIUS PHARMA COPRORATION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com